Aesthetics Challenger Poised for Major Expansion – FDA Decision Looms
We assign a 60.5% probability that the FDA will grant approval in early 2025.
For the past six years, a fast-growing aesthetics company has been carving out a space in the competitive neurotoxin market, steadily increasing sales of its flagship product as a direct challenger to Botox. Along the way, it expanded its portfolio with an additional product for frown lines and other aesthetic applications.
Now, this company is preparing to launch two injectable treatments designed to address facial wrinkles and folds, leveraging a well-established compound widely used for both cosmetic and medical purposes. These treatments have already demonstrated non-inferiority to a leading dermal filler that has been on the market for over 25 years. If approved, this will mark the company’s most significant expansion yet. We assign a 60.5% probability that the FDA will grant approval in early 2025.
We assign a 60.5% probability that the FDA will grant approval in early 2025.
MACE Scores are based on:
Market Demand
Adoption by payers and key opinion leaders (KOLs)
Clinical progress
Experience and capital.